Application

Antibody is recommended for use in immunoblotting, immunoprecipitation and immunofluorescence..

Anti-c-Myc antibody has been used in western blotting and immunofluorescence.

Biochem/physiol Actions

MYC (MYC proto-oncogene) may be essential for cancer initiation, promotion and therapy resistance. Overexpression of MYC in DLBCL (diffuse large B-cell lymphoma) results in poor outcome and invasive treatment when medicated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The cellular myelocytomatosis (c-myc) oncogene plays a major role in cellular proliferation, differentiation and apoptosis. It acts as transcriptional regulator of gene expression.

General description

MYC (MYC proto-oncogene) is a transcriptional factor and oncoprotein. It is located on chromosome 8q24. c-Myc gene codes for basic helix-loop-helix/leucine zipper (bHLH/LZ) transcription factor.

Anti-c-Myc antibody is used for the detection of the c-Myc tag sequence on c-Myc tagged fusion proteins.This polyclonal antibody is produced in rabbit and recognizes the c-Myc sequence at the N-terminus and C-terminus. C3956 is an Affinity purified antibody, increasing sensitivity in most applications.

Immunogen

peptide corresponding amino acids 408-425 of the human c-myc proto-oncogene, conjugated to maleimide-activated KLH through a C-terminal added cysteine residue.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 1% bovine serum albumin and 15 mM sodium azide.

Specificity

N-terminal or C-terminal c-Myc (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu) tagged fusion proteins.